Cutaneous Lupus Erythematosus

Evidence-Based Dermatology: Second Edition

Volumn , Issue , 2009, Pages 547-558

  Jessop, Susan ^a   Whitelaw, David ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Amodiaquine and quinacrine; Chloroquine and quinacrine combination in people with chronic cutaneous lupus; Cutaneous lupus by clinical examination, skin biopsy; Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI); Systemic lupus erythematosus (SLE); Topical agent effects in cutaneous lupus

Indexed keywords

EID: 84889314086     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300161.ch55     Document Type: Chapter

References (167)

1. Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996;135:355-62.
2. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981;4: 471-5.
3. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979;115:1409-15.
4. Hochberg MC. The epidemiology of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus. Philadelphia: Lea and Febiger, 1993:49-57.
5. Isenberg DA. Systemic lupus erythematosus: immunopathogen-esis and the card game analogy. J Rheumatol 1997;24:62-6.
6. Arnett FC. The genetic basis of lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus. Philadelphia: Lea and Febiger, 1993:13-36.
7. Millard TP, McGregor JM. Molecular genetics of cutaneous lupus erythematosus. Clin Exp Dermatol 2001;26:184-91.
8. Vaughan JH. Viruses and autoimmune disease. J Rheumatol 1996;23:1831-3.
9. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus erythematosus disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889-94.
10. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001;1:CD002954.
11. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992;127:513-8.
12. Bezerra EL, Vilar MJ, da Trindade Nedo, et al. Double blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:3073-8.
13. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
14. Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of mild systemic lupus erythematosus. J Rheumatol 1994;21:1457-62.
15. Meinao IM, Sato EI, Andrade LE, et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996;5:237-41.
16. Kraak JH, van Ketel WG, Prakken JR. The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus: a double blind trial. Dermatologica 1965; 130:293-305.
17. Christiansen JV. Treatment of lupus erythematosus with chloro-quine. Br J Dermatol 1957;69:158-68.
18. Brodthagen H. Hydroxychloroquine (Plaquenil) in the treatment of lupus erythematosus. Acta Derm Venereol 1959;39:233-7.
19. Crissey JT, Murray PF. A comparison of chloroquine and gold in the treatment of lupus erythematosus. Arch Dermatol 1956;74: 69-72.
20. Galla F. L'idrossiclorochina nel trattamento dell'eritematodes cronico. Minerva Dermatol 1961;36:99-101.
21. Goode P. Plaquenil in the treatment of cutaneous lupus erythematosus. Br J Dermatol 1958;70:176-8.
22. Tye MJ, Schiff BL, Collins SF, Baler GR, Appel B. Chronic discoid lupus erythematosus. Treatment with Daraprim and chloro-quine diphosphate (Aralen). N Engl J Med 1954; 251:52-5.
23. Kuhn A, Richter-Hinz D, Oslislo C, et al. Lupus erythematosus tumidus. Arch Dermatol 2000;136:1033-41.
24. Choonhakarn C, Poonsriaram A, Chaivoremukul J. Lupus erythematosus tumidus. Int J Dermatol 2004;43:815-8.
25. Houpt JB. A rheumatologist's verdict on the safety of chloro-quine versus hydroxychloroquine. J Rheumatol 1999:26:1864-7.
26. Sontheimer R. Questions answered and a $1 million question raised concerning lupus erythematosus tumidus. Arch Dermatol 2000;136:1044-9.
27. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis Rheum 1990; 33:1449-59.
28. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10:401-4.
29. Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 1989;18:282-96.
30. Maguire A. Amodiaquine hydrochloride in the treatment of chronic discoid lupus erythematosus. Lancet 1962;31:665-7.
31. Leeper RW, Allende MF. Antimalarials in the treatment of discoid lupus erythematosus. Arch Dermatol 1956;73:50-7.
32. Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994;189:425-7.
33. Lipsker D, Piette JC, Cacoub P, Godeau P, Frances C. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995;190:257-8.
34. Tye MJ, White H, Appel B, Ansell HB. Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine. N Engl J Med 1959;260:63-5.
35. Von Schmiedeberg S, Ronnau AC, Schuppe HC, Specker C, Ruzicka T, Lehmann P. [Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus; in German.] Hautarzt 2000; 51:82-5.
36. Everett MA, Coffey CM. Intradermal administration of chloro-quine for discoid lupus erythematosus and lichen sclerosis et atrophicus. Arch Dermatol 1961;83:977-9.
37. Pelzig A, Witten VH, Sulzberger MB. Chloroquine for chronic discoid lupus erythematosus. Arch Dermatol 1961;83:146-8.
38. Callen JP. Chronic cutaneous lupus erythematosus. Arch Dermatol 1982;118:412-6.
39. Alexander S, Cowan MA. The treatment of chronic discoid lupus erythematosus with a combination of antimalarial and corticosteroid drugs. Br J Dermatol 1961;73:359-61.
40. Da Silva JAP, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
41. Smith JF. Intralesional triamcinolone as an adjunct to antimalar-ial drugs in the treatment of chronic discoid lupus erythematosus. Br J Dermatol 1962;74:350-3.
42. James APR. Intradermal triamcinolone acetonide in localized lesions. J Invest Dermatol 1980;34:175-6.
43. Kraak JH. [Local treatment of chronic lupus erythematosus with triamcinolone injections; in Dutch.] Ned Tijdschr Geneeskd 1964; 108:1305-6.
44. Rowell NR. Treatment of chronic discoid lupus erythematosus with intralesional triamcinolone. Br J Dermatol 1962;74:354-7.
45. Dupré A, Bonafé JL, Lassére J, Albarel N, Christol B. Traitement du lupus érythémateux chronique par le lampréne. Ann Dermatol Venereol (Paris) 1978;105:423-5.
46. Krivanek J, Paver WKA, Kossard S. (Lamprone) in the treatment of discoid lupus erythematosus. Dermatol 1976;17:108-10.
47. Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol 1974;91:93-6.
48. Jakes JT, Dubois EL, Quismorio FP. Antileprosy drugs and lupus erythematosus. Ann Intern Med 1982;97:788.
49. Arbiser JL, Moschella SL. Clofazimine: review of its medical uses and mechanisms of action. J Am Acad Dermatol 1995;32:241-7.
50. Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol 1982;106:105-6.
51. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986;172:214-7.
52. Ruzicka T, Goerz G. Dapsone in the treatment of lupus erythematosus. Br J Dermatol 1981;104:53-5.
53. Bohm I, Bruns A, Schupp G, Bauer R. [ANCA-positive lupus erythematodes profundus. Successful therapy with low dosage dapsone; in German.] Hautarzt 1998; 49:403-7.
54. Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982; 97:165-70.
55. Holtman JH, Neustadt DH, Klein J, Callen JP. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990;17:1222-5.
56. McCormack LS, Elgart ML, Turner MLC. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984;11:397-401.
57. Neri R, Mosca M, Bernacchi E, Bombardieri S. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus 1999;8:240-3.
58. Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996;35:313-5.
59. Mok CC, Lau, CS, Wong RW. Toxicities of dapsone in the treatment of cutaneous manifestations of rheumatic diseases. J Rheumatol 1998;25:1246-7.
60. Carneiro JR, Sato EI. Double blind, randomized, placebo-controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999;26:1275-9.
61. Wenzel J, Brahler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br. J Dermatol 2005; 153:157-62.
62. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997;56:382-5.
63. Wilson J, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:1674-7.
64. Arfi S, Numeric P, Grollier L, Panelatti G, Jean-Baptiste G. [Treatment of corticodependent systemic lupus erythematosus with low dose methotrexate; in French.] Rev Med Interne 1995; 16:885-90.
65. Davidson JR, Graziano FM, Rothenberg RJ. Methotrexate therapy for severe systemic lupus erythematosus. Arthritis Rheum 1987;30:1195-6.
66. Garcia G, Portales G, Nebro F, et al. Effectiveness of the treatment of systemic lupus erythematosus with methotrexate. Med Clin (Barc) 1993;101:361-4.
67. Bohm L, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997;194:307-8.
68. Rothenberg RJ, Graziano FM, Grandone JT, et al. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988;31:612-5.
69. Walz LeBlanc BAE, Dagenais P, Urowitz MB, Gladman DD. Methotrexate in systemic lupus erythematosus. J Rheum 1994; 21:836-8.
70. Bottomley WW, Goodfield M. Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol 1995;133:311-4.
71. Malcangi G, Brandozzi G, Giangiacomi M, et al. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus 2003;12:63-6.
72. Kuhn A, Specker, Ruzicka T. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002;46:600-3.
73. McKendry RJR. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997;23:939-45.
74. Grupper C, Berretti B. Lupus erythematosus and etretinate. In: Cunliffe W, Miller A, eds. Retinoid Therapy: a Review of Clinical and Laboratory Research. Lancaster: MTP Press, 1984:73-81.
75. Ruzicka T, Meurer M, Braun-Falco O. Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 1985; 65:324-9.
76. Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988; 124:897-902.
77. Furner BB. Subacute cutaneous lupus erythematosus. Response to isotretinoin. Int J Dermatol 1990; 29:587-90.
78. Green SG, Piette WW. Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol 1987;17:364-8.
79. Marks R. Lichen planus and cutaneous lupus erythematosus. In: Lowe N, Marks R, eds. Retinoids. London: Dunitz, 1995:1437.
80. Newton RC, Jorizzo JL, Solomon AR, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986;122:170-6.
81. Rubenstein DJ, Huntley AC. Keratotic lupus erythematosus: treatment with isotretinoin. J Am Acad Dermatol 1986;14:910-4.
82. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991;24:49-52.
83. Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis 1991;47:351-5.
84. Lowe NJ, David M. Toxicity. In: Lowe N, Marks R, eds. Retinoids. A Clinician's Guide. London: Dunitz, 1998:149-65.
85. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Derm 1983;108:461-6.
86. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997;36:353-9.
87. Samsoen M, Grosshans E, Basset A. La thalidomide dans le traitement du lupus érythémateux chronique. Ann Dermatol Venereol 1980;107:515-23.
88. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993;11:487-93.
89. Ordi-Ros J, Cortes F, Cucurull E, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000;27:1429-33.
90. Duong DJ, Spigel T, Moxley RT, et al. American experience with low dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999;135:1079-87.
91. Hasper MF. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Arch Dermatol 1983; 119:812-5.
92. Naafs B, Faber WR. Thalidomide therapy. An open trial. Int J Dermatol 1985; 24:131-4.
93. Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus 2005;14:434-9.
94. Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005;118:246-50.
95. Gambini D, Carrera C, Passoni E, et al. Thalidomide treatment for hypertrophic cutaneous lupus erythematosus. J Dermatolog Treat 2004;15:365-71.
96. Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996;35:969-79.
97. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108:487-95.
98. Briani C, Zara G, Rondinone R, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity 2005;38:549-55.
99. Callen J, Spencer LV, Burruss JB, Holtman J. Azathioprine. Arch Dermatol 1991;127:515-22.
100. Ashinoff R, Werth VP, Franks AG. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988;19:961-5.
101. Shehade S. Successful treatment of generalised discoid skin lesions with azathioprine. Arch Dermatol 1986;122:376-7.
102. Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalised discoid skin lesions with azathioprine. Arch Dermatol 1985;121:1323-5.
103. Yell JA, Burge SM. Cyclosporin and discoid lupus erythematosus. Br J Dermatol 1994;131:132-3.
104. Saeki Y, Ohshima S, Kurimoto I, Miura H, Suemura M. Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 2000;9:390-2.
105. Di Lernia V, Biosighini G. Discoid lupus erythematosus during treatment with cyclosporine. Acta Derm Venereol 1996;76: 87-8.
106. Obermoser G, Weber F, Sepp N. Discoid lupus erythematosus in a patient receiving cyclosporin for liver transplantation. Acta Derm Venereol 2001;81:319.
107. Wright CS. Ten years experience in the treatment of lupus erythematosus with gold compounds. Arch Dermatol Syph 1936; 33:413-29.
108. Rutledge WU. Lupus erythematosus. Treatment with gold preparations. Arch Dermatol Syph 1931; 23:874-83.
109. Strandberg J. Six years' experience of the treatment of lupus erythematosus with gold compounds. Acta Med Scand 1931;75: 296-317.
110. Pascher F. Treatment of lupus erythematosus with calciferol, antibiotics and gold preparations. Arch Dermatol Syph 1950;61: 906-12.
111. Dalziel K, Going G, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol 1986;115:211-6.
112. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001;45:142-4.
113. Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005;23:393-6.
114. Rodriguez-Castellanos MA, Rubio JB, Gomez JFB, Mendonza AG. Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol 1995;131:620-1.
115. Morgan J. A note on the treatment of lupus erythematosus with vitamin E. Br J Dermatol 1951;63:224-5.
116. Burgess JF, Pritchard JE. Tocopherols (vitamin E). Treatment of lupus erythematosus: preliminary report. Arch Dermatol Syph 1948; 57:953-64.
117. Pascher F, Sawicky HH, Silverberg MF, et al. Tocopherol (vitamin E) for discoid lupus erythematosus and other dermatoses. J Invest Dermatol 1951;17:261-2.
118. Sawicky HH. Therapy of lupus erythematosus. Arch Dermatol Syph 1950;61:906-9.
119. Sweet RD. Vitamin E in collagenoses. Lancet 1948;ii:310-1.
120. Yell JA, Burge S, Wojnarowska F. Vitamin E and discoid lupus erythematosus. Lupus 1992;1:303-5.
121. Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumour necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003;7:382-6.
122. Norman R, Greenberg RG, Jackson M. Case reports of etaner-cept in inflammatory dermatoses. J Am Acad Dermatol 2006;54 (3 Suppl 2):S139-42.
123. Scheinfeld N. The medical uses and side effects of etanercept with a focus on cutaneous disease. J Drugs Dermatol 2004;3:653-9.
124. Stratigos AJ, Antoniou C, Stamathioudaki S, et al. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exper Dermatol 2004;29:150-3.
125. Prinz JC, Meurer M, Reiter C, et al. Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 1996;34:244-52.
126. Roenigk HH, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980; 25:281-5.
127. Bjornberg A, Hellgren L. Topical treatment of chronic discoid lupus erythematosus with betamethason-17-valerate and fluo-cinolone acetonideaa double blind study. Indian J Dermatol 1966; 12:17-8.
128. Bjornberg A, Hellgren L. Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment. Br J Dermatol 1963;75:156-60.
129. Bjornberg A, Hellgren L. Treatment of chronic discoid lupus erythematosus with betamethasone-17,21 dipropionate. Curr Ther Res 1976;19:442-3.
130. Haneke E. Long-term treatment with 6 α-methylprednisolone aceponate. J Eur Acad Dermatol Venereol 1994;3:S19-S22.
131. Jansen GT, Dillaha CJ, Honeycutt WM. Discoid lupus erythematosus. Arch Dermatol 1965;92:283-5.
132. Marsden CW. Fluocinolone acetonide 0.2% cream-a cooperative clinical trial. Br J Dermatol 1968; 80:614-7.
133. Mitchell AD, Mitchell DM. Fluocinolone acetonide in the treatment of chronic discoid lupus erythematosus. Lancet 1962; ii:359.
134. Reymann F. Treatment of discoid lupus erythematosus with betamethasone-valerate cream 1%. Dermatologica 1974;149:65-8.
135. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of glucocorticosteroids. J. Am Acad Dermatol 2006;54:1-15.
136. T-y. Tzung, y-s. Liu, h-w. Chang Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. British Journal of Dermatology 2007;156(1):191-192.
137. Walker SL, Kirby B, Chalmers RJG. Letter. Eur J Dermatol 2002; 12:387-8.
138. Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003;148:353-6.
139. Böhm M, Gaubitz M, Luger TA, Metze D, Bonsmann G. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology (Basel) 2003; 207:381-5.
140. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004;51:407-10.
141. Lampropoulos CE, Sangle S, Harrison P, Hughes GRV, D'Cruz DP. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004;43:1383-5.
142. Heffernan MP, Nelson MM, Smith DI, Chung JH. 1% Tacrolimus ointment in the treatment of discoid lupus erythematosus. Arch Dermatol 2005;141:1170-1
143. Yoshimasu T, Ohtani T, Oshima A, Sakamoto T, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002;12:50-2.
144. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. Br Med J 2005;330:516.
145. Becker JC, Houben R, Vetter CS, Eva B. The carcinogenic potential of tacrolimus ointment suppression; a hypothesis creating case report. BMC Cancer 2006;6:7-11.
146. Stege H, Budde MA, Grether-Beck S, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photoderm Photoimmunol Photomed 2000;16:256-9.
147. Callen JP, Roth DE, McGrath C, Dromgoole SH. Safety and efficacy of a broad-spectrum sunscreen in patients with discoid or subacute cutaneous lupus erythematosus. Cutis 1991;47:130-2.
148. Cornbleet T, Barsky S, Hoit L. Discoid lupus erythematosus scars treated by plastic surgery. Arch Dermatol 1957;74:219.
149. Neuman Z, Shulman J, Ben-hur N. Successful skin grafting in discoid lupus erythematosus. Ann Surg 1961;154:142-4.
150. Friederich HC. [Skin moving and skin transplantation in chronic lupus erythematosus integumentalis; in German.] Hautarzt 1969; 20:119-22.
151. Kurwa AR, Evans AJ. Discoid lupus erythematosus treated by dermabrasion. Br J Dermatol 1970;101:S53.
152. Schiödt M. Local excision in the treatment of oral discoid lupus erythematosus. Acta Derm Venereol Suppl 1978;59:274-6.
153. Ratner D, Skouge JW. Discoid lupus erythematosus scarring and dermabrasion: a case report and discussion. J Am Acad Dermatol 1990;22:314-6.
154. Polderman MC, Huizinga, TW, Le-Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial. Ann Rheum Dis 2001;60:112-5.
155. McGrath H. Ultraviolet A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:129-35.
156. Molina JF, McGrath H. Long-term ultraviolet-A1 irradiation therapy in systemic lupus erythematosus. J Rheum 1997;24:1072-4.
157. Sonnichsen NH, Meffert V, Kunzelmann V, Audring H. UVA1 therapy of subacute cutaneous lupus erythematosus. Hautarzt 1993;44:723-5.
158. Richter HI, Krutmann J, Goerz G. Extracorporeal photopheresis in therapy-refractory disseminated discoid lupus erythematosus. Hautarzt 1998;49:487-91.
159. Wollina U, Looks A. Extracorporeal photochemotherapy in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 1999;13:127-30.
160. Knobler RM, Graninger W, Graninger W, Lindmaier A, Trautinger F, Smolen JS. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthritis Rheum 1992;35:319-24.
161. Raulin C, Schmidt C, Hellwig S. Cutaneous lupus erythematosus: treatment with pulsed dye laser. Br J Dermatol 1999;141:1046-50.
162. Gupta G, Roberts DT. Pulsed dye laser treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1999;24:498-9.
163. Núñez M, Boixeda P, Miralles ES, de Misa RF, Ledo A. Pulsed dye laser treatment of telangiectatic chronic erythema of cutaneous lupus erythematosus. Arch Dermatol 1996;132:354-5.
164. Zachariae H, Bjerring P, Cramers M. Argon laser treatment of cutaneous vascular lesions in connective tissue diseases. Acta Derm Venereol 1952;68:179-82.
165. Nürnberg W, Algermissen B, Hermes B, Henz BM, Kolde G. [Successful treatment of chronic discoid lupus erythematosus with argon laser; in German.] Hautarzt 1996; 47:767-70.
166. Kuhn A, Becker-Wegerich PM, Ruzicka T, Lehmann P. Successful treatment of discoid lupus erythematosus with argon laser. Dermatology 2000;201:175-7.
167. Baniandres O, Boixeda P, Belmar P, Perez A. Treatment of lupus erythematosus with pulsed dye laser. Lasers Surg Med 2003;32: 327-30.